Wednesday, July 8, 2026

biotech · Post Traumatic Stress Disorder · Prosthetic Joint Infection · ADPT

Adaptive Biotechnologies

Adaptive Biotechnologies patent portfolio — 12 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.

1165 Eastlake Ave E, Seattle, Washington 98109, US HQ
2009 Founded
659 Employees
Public company Type
ADPT · NYSE Ticker
Company details
Status
Public
HQ
1165 Eastlake Ave E, Seattle, Washington 98109, US
Founded
2009
Employees
659
Programs
19
Drugs
23
Patents
12
Intelligence · Patents

Adaptive Biotechnologies patents

12 pharmaceutical patents indexed for Adaptive Biotechnologies. 0 expire within 24 months.

Adaptive Biotechnologies has 12 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.

Patent portfolio

  1. US 12264187

    Compositions and methods for targeted therapeutic delivery to bone

    Expires Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  2. US 12263179

    Lyme disease-associated T cell receptor-related methods

    Expires Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  3. US 12266425

    T cell receptor sequences diagnostic for COVID-19 and related compositions

    Expires Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  4. US 12006517

    Method for purification of bacteriophage particles

    Expires Mon Jun 06 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  5. US 11911345

    Phage dispensing system

    Expires Mon Feb 22 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  6. US 11773138

    Polypeptides including a beta-tricalcium phosphate-binding sequence and uses thereof

    Expires Mon Sep 28 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  7. US 11390921

    Determining WT-1 specific T cells and WT-1 specific T cell receptors (TCRs)

    Expires Mon Jul 14 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  8. US 11192923

    Polypeptides including a beta-tricalcium phosphate-binding sequence and uses thereof

    Expires Mon Dec 02 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  9. US 11191780

    Extracellular matrix compositions for the treatment of cancer or immunological diseases

    Expires Mon Dec 02 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  10. US 11041202

    Method of identifying human compatible T cell receptors specific for an antigenic target

    Expires Mon Jun 17 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  11. US 11026969

    High affinity T cell receptors and uses thereof

    Expires Mon Jun 03 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  12. US 10675303

    Extracellular matrix compositions for the treatment of cancer

    Expires Mon Jun 04 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Adaptive Biotechnologies have?

12 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Adaptive Biotechnologies patents expire?

0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.